Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCAT | P04180 | 1/20 | 0.42 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.42 |
| ▸ | PDE4A | P27815 | 2/20 | 0.42 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.42 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.42 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.42 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | USP7 | Q93009 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.31 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL628617 | 0.87 | TSHR (0.39) | LCATCHRM3PDE4APDE4BPDE4C | |
| SCHEMBL19399166 | 0.81 | CHRM3 (0.47) | LCATCHRM3PDE4APDE4BPDE4C | |
| SCHEMBL3694402 | 0.79 | GPR119 (0.59) | LCATCHRM3PDE4APDE4BPDE4C | |
| SCHEMBL19454413 | 0.78 | GPR119 (0.46) | LCATCHRM3PDE4APDE4BPDE4C | |
| SCHEMBL17115090 | 0.78 | PDE10A (0.44) | LCATCHRM3PDE4APDE4BPDE4C | |
| SCHEMBL11956862 | 0.74 | CHRM3 (0.45) | LCATCHRM3PDE4APDE4BPDE4C | |
| SCHEMBL1103825 | 0.74 | CHRM3 (0.44) | LCATCHRM3PDE4APDE4BPDE4C | |
| SCHEMBL14730239 | 0.74 | GPR119 (0.43) | LCATCHRM3PDE4APDE4BPDE4C | |
| SCHEMBL21608104 | 0.74 | GPR119 (0.35) | CHRM3PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL12506093 | 0.73 | GPR119 (0.56) | LCATCHRM3PDE4APDE4BPDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3440087-B1 | THIAZOLOPYRIDINE DERIVATIVES AS GPR119 AGONISTS | MANKIND PHARMA LTD (IN) | 2022-08-10 | — | — | EP | disclosed |
| CN-109415381-B | Thiazolopyridine derivatives as GPR119 agonists | 人类制药有限公司 | 2022-03-25 | — | — | CN | disclosed |
| US-10919915-B2 | Compounds as GPR119 agonists | MANKIND PHARMA LTD. (IN) | 2021-02-16 | — | — | US | disclosed |
| US-10919915-B2 | Compounds as GPR119 agonists | MANKIND PHARMA LTD. (IN) | 2021-02-16 | — | — | US | disclosed |
| US-20200040006-A1 | NOVEL COMPOUNDS AS GPR119 AGONISTS | MANKIND PHARMA LTD. (IN) | 2020-02-06 | — | — | US | disclosed |
| US-20200040006-A1 | NOVEL COMPOUNDS AS GPR119 AGONISTS | MANKIND PHARMA LTD. (IN) | 2020-02-06 | — | — | US | disclosed |
| EP-3440087-A1 | THIAZOLOPYRIDINE DERIVATIVES AS GPR119 AGONISTS | MANKIND PHARMA LTD (IN) | 2019-02-13 | — | — | EP | disclosed |
| US-20170291910-A1 | NOVEL COMPOUNDS AS GPR119 AGONISTS | MANKIND PHARMA LTD. (IN) | 2017-10-12 | — | — | US | disclosed |
| US-20170291910-A1 | NOVEL COMPOUNDS AS GPR119 AGONISTS | MANKIND PHARMA LTD. (IN) | 2017-10-12 | — | — | US | disclosed |
| US-20170291910-A1 | NOVEL COMPOUNDS AS GPR119 AGONISTS | MANKIND PHARMA LTD. (IN) | 2017-10-12 | — | — | US | disclosed |
| WO-2017175068-A1 | THIAZOLOPYRIDINE DERIVATIVES AS GPR119 AGONISTS | MANKIND PHARMA LTD. (IN) | 2017-10-12 | — | — | WO | disclosed |
| WO-2017175068-A1 | THIAZOLOPYRIDINE DERIVATIVES AS GPR119 AGONISTS | MANKIND PHARMA LTD. (IN) | 2017-10-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200040006-A1 | NOVEL COMPOUNDS AS GPR119 AGONISTS | GPR119, GPR84, GPR65 | LCAT 478/4885CHRM3 172/4885PDE4A 499/4885 |
| US-20170291910-A1 | NOVEL COMPOUNDS AS GPR119 AGONISTS | GPR119, GPR84, GPR65 | LCAT 478/4885CHRM3 172/4885PDE4A 499/4885 |
| US-10919915-B2 | Compounds as GPR119 agonists | GPR119, GPR84, GPR65 | LCAT 407/4885CHRM3 141/4885PDE4A 498/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.